1. Zimmet P, Alberti KG, Magliano DJ, Bennett PH: Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol 2016, 12(10):616-622.
2. Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, Shi B, Sun H, Ba J, Chen B et al: Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 2020, 369:m997.
3. Goodarzi MO, Rotter JI: Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease. Circ Res 2020, 126(11):1526-1548.
4. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H: Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44 Suppl 2:S14-21.
5. Henning RJ: Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol 2018, 14(6):491-509.
6. Glovaci D, Fan W, Wong ND: Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep 2019, 21(4):21.
7. Boudoulas KD, Triposciadis F, Geleris P, Boudoulas H: Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. Prog Cardiovasc Dis 2016, 58(6):676-692.
8. Milutinovic A, Suput D, Zorc-Pleskovic R: Pathogenesis of atherosclerosis in the tunica intima, media, and adventitia of coronary arteries: An updated review. Bosn J Basic Med Sci 2020, 20(1):21-30.
9. Tousoulis D, Simopoulou C, Papageorgiou N, Oikonomou E, Hatzis G, Siasos G, Tsiamis E, Stefanadis C: Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches. Pharmacol Ther 2014, 144(3):253-267.
10. Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, Baker AH: Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019, 73(2):190-209.
11. Souilhol C, Harmsen MC, Evans PC, Krenning G: Endothelial-mesenchymal transition in atherosclerosis. Cardiovasc Res 2018, 114(4):565-577.
12. Islam S, Bostrom KI, Di Carlo D, Simmons CA, Tintut Y, Yao Y, Hsu JJ: The Mechanobiology of Endothelial-to-Mesenchymal Transition in Cardiovascular Disease. Front Physiol 2021, 12:734215.
13. Nakajima Y, Yamagishi T, Hokari S, Nakamura H: Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec 2000, 258(2):119-127.
14. Chen PY, Schwartz MA, Simons M: Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis. Front Cardiovasc Med 2020, 7:53.
15. Chen PY, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, Tellides G, Schwartz MA, Simons M: Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest 2015, 125(12):4514-4528.
16. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, d'Escamard V, Li JR, Hadri L, Fujitani K et al: Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun 2016, 7:11853.
17. Guo J: Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. Chin J Integr Med 2017, 23(6):403-409.
18. Hu X, Wang M, Bei W, Han Z, Guo J: The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome. J Transl Med 2014, 12:47.
19. Guo J, Bei W, Hu Y, Tang C, He W, Liu X, Huang L, Cao Y, Hu X, Zhong X et al: A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats. J Ethnopharmacol 2011, 135(2):299-307.
20. Luo D, Li J, Chen K, Rong X, Guo J: Untargeted Metabolomics Reveals the Protective Effect of Fufang Zhenshu Tiaozhi (FTZ) on Aging-Induced Osteoporosis in Mice. Front Pharmacol 2018, 9:1483.
21. Li T, Zhang R, Liu Y, Yao Y, Guo J, Zeng Z: Fufang-Zhenzhu-Tiaozhi capsule ameliorates rabbit's iliac artery restenosis by regulating adiponectin signaling pathway. Biomed Pharmacother 2020, 128:110311.
22. Zhang R, Li T, Guo J, Zhao Y, Liu Y, Yao Y, Zeng Z: Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits. Lipids Health Dis 2018, 17(1):272.
23. Tang CP, Jiang T, Guo J, Wei YP, Yang CY, Chen FC: [The effect of fufang zhenzhu tiaozhi capsule on lipid metabolism in atherosclerotic rabbits]. Zhong Yao Cai 2010, 33(8):1285-1289.
24. Song L, Zhang D, Guo C, Gu Z, Wang L, Yao YS, Wang H, Zeng Z, Wang W, Yang Y et al: The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease. Biomed Pharmacother 2021, 137:111343.
25. Thim T, Hagensen MK, Drouet L, Bal Dit Sollier C, Bonneau M, Granada JF, Nielsen LB, Paaske WP, Botker HE, Falk E: Familial hypercholesterolaemic downsized pig with human-like coronary atherosclerosis: a model for preclinical studies. EuroIntervention 2010, 6(2):261-268.
26. Thim T, Hagensen MK, Wallace-Bradley D, Granada JF, Kaluza GL, Drouet L, Paaske WP, Botker HE, Falk E: Unreliable assessment of necrotic core by virtual histology intravascular ultrasound in porcine coronary artery disease. Circ Cardiovasc Imaging 2010, 3(4):384-391.
27. Patel D, Hamamdzic D, Llano R, Patel D, Cheng L, Fenning RS, Bannan K, Wilensky RL: Subsequent development of fibroatheromas with inflamed fibrous caps can be predicted by intracoronary near infrared spectroscopy. Arterioscler Thromb Vasc Biol 2013, 33(2):347-353.
28. Cheng Y, Ferrone M, Wang Q, Perkins LEL, McGregor J, Redfors B, Zhou Z, Rapoza R, Conditt GB, Finn A et al: Impact of Coronary Atherosclerosis on Bioresorbable Vascular Scaffold Resorption and Vessel Wall Integration. JACC Basic Transl Sci 2020, 5(6):619-629.
29. Slottow TL, Pakala R, Okabe T, Hellinga D, Lovec RJ, Tio FO, Bui AB, Waksman R: Optical coherence tomography and intravascular ultrasound imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries. Cardiovasc Revasc Med 2008, 9(4):248-254.
30. Gasior P, Cheng Y, Valencia AF, McGregor J, Conditt GB, Kaluza GL, Granada JF: Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis. Circ Cardiovasc Interv 2017, 10(5).
31. Koskinas KC, Feldman CL, Chatzizisis YS, Coskun AU, Jonas M, Maynard C, Baker AB, Papafaklis MI, Edelman ER, Stone PH: Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study. Circulation 2010, 121(19):2092-2101.
32. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
33. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A: Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018, 14(10):576-590.
34. Kunnumakkara AB, Shabnam B, Girisa S, Harsha C, Banik K, Devi TB, Choudhury R, Sahu H, Parama D, Sailo BL et al: Inflammation, NF-kappaB, and Chronic Diseases: How are They Linked? Crit Rev Immunol 2020, 40(1):1-39.
35. Ljubkovic M, Gressette M, Bulat C, Cavar M, Bakovic D, Fabijanic D, Grkovic I, Lemaire C, Marinovic J: Disturbed Fatty Acid Oxidation, Endoplasmic Reticulum Stress, and Apoptosis in Left Ventricle of Patients With Type 2 Diabetes. Diabetes 2019, 68(10):1924-1933.
36. Sun J, Singh P, Osterlund J, Orho-Melander M, Melander O, Engstrom G, Edsfeldt A: Hyperglycaemia-associated Caspase-3 predicts diabetes and coronary artery disease events. J Intern Med 2021.
37. Pardali E, Sanchez-Duffhues G, Gomez-Puerto MC, Ten Dijke P: TGF-beta-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. Int J Mol Sci 2017, 18(10).
38. Ma J, Sanchez-Duffhues G, Goumans MJ, Ten Dijke P: TGF-beta-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering. Front Cell Dev Biol 2020, 8:260.
39. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005, 111(25):3481-3488.
40. Bischoff J: Endothelial-to-Mesenchymal Transition. Circ Res 2019, 124(8):1163-1165.
41. Libby P: Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
42. Rizzacasa B, Amati F, Romeo F, Novelli G, Mehta JL: Epigenetic Modification in Coronary Atherosclerosis: JACC Review Topic of the Week. J Am Coll Cardiol 2019, 74(10):1352-1365.
43. Westerterp M, Fotakis P, Ouimet M, Bochem AE, Zhang H, Molusky MM, Wang W, Abramowicz S, la Bastide-van Gemert S, Wang N et al: Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation 2018, 138(9):898-912.
44. Niyonzima N, Bakke SS, Gregersen I, Holm S, Sandanger O, Orrem HL, Sporsheim B, Ryan L, Kong XY, Dahl TB et al: Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis. EBioMedicine 2020, 60:102985.
45. Martinez GJ, Celermajer DS, Patel S: The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 2018, 269:262-271.
46. Jain T, Nikolopoulou EA, Xu Q, Qu A: Hypoxia inducible factor as a therapeutic target for atherosclerosis. Pharmacol Ther 2018, 183:22-33.
47. Roshan MH, Tambo A, Pace NP: The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis. Int J Inflam 2016, 2016:1532832.
48. Mitchell S, Vargas J, Hoffmann A: Signaling via the NFkappaB system. Wiley Interdiscip Rev Syst Biol Med 2016, 8(3):227-241.
49. Wang L, Wu H, Deng Y, Zhang S, Wei Q, Yang Q, Piao S, Bei W, Rong X, Guo J: FTZ Ameliorates Diabetic Cardiomyopathy by Inhibiting Inflammation and Cardiac Fibrosis in the Streptozotocin-Induced Model. Evid Based Complement Alternat Med 2021, 2021:5582567.
50. Wang C, Niimi M, Watanabe T, Wang Y, Liang J, Fan J: Treatment of atherosclerosis by traditional Chinese medicine: Questions and quandaries. Atherosclerosis 2018, 277:136-144.
51. Zhang J, Meng H, Zhang Y, Zhang X, Shao M, Li C, Tu P: The Therapeutical Effect of Chinese Medicine for the Treatment of Atherosclerotic Coronary Heart Disease. Curr Pharm Des 2017, 23(34):5086-5096.
52. Wang L, Xiang L, Piao S, Gong X, Zhou W, Feng W, Li H, Li L, Wei A, Zhu Q et al: The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes Metab Syndr Obes 2021, 14:2651-2659.
53. Chen Y, He X, Yuan X, Hong J, Bhat O, Li G, Li PL, Guo J: NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ. Oxid Med Cell Longev 2018, 2018:2901871.